Hepatitis C Virus (HCV)

CAS No.	Product Name	Inquiry
640725-71-9	Valopicitabine dihydrochloride Valopicitabine dihydrochloride is a nucleoside analogue and the orally bioavailable 2'-C-methylcytidine (NM107) prodrug, with anti-hepatitis C virus (HCV) activity.
641-12-3	SENNIDINE A Sennidin A-stimulated glucose incorporation was completely inhibited by wortmannin. Sennidin A did not induce tyrosine phosphorylation of insulin receptor (IR) and insulin receptor substrate-1 (IRS-1), but induced phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Our results suggest that in rat adipocytes, sennidin A stimulates glucose incorporation in the phosphatidylinositol 3-kinase (PI3K)- and Akt-dependent, but in the IR/IRS1-independent manner.
67401-56-3	Micrococcin P1 It is a thiopeptide antibiotic isolated from the culture broth of Bacillus pumilus as a main component of the micrococcin P complex.
67700-30-5	R803 R803 is a potent and highly specific HCV replication inhibitor with EC50s of about 30 nM for genotype 1a and 1b replicons, and an EC50 of about 1,000 nM for genotype 2a replicon.
690270-29-2	Balapiravir Balapiravir is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase. It is the tri-isobutyrate ester prodrug of R1479 under clinical development to improve exposure of R1479 upon oral administration. It was discontinued for safety reasons in 28-36% of patients and the percentage of patients with serious adverse events was dose related.
690270-65-6	Balapiravir hydrochloride Balapiravir hydrochloride is an orally active prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp). It is an NS5B inhibitor that has the potential to treat HCV infection.
691852-58-1	Nesbuvir Nesbuvir, a novel selective nonstructural protein 5B (NS5B) polymerase inhibitor, acts as candidate for HCV treatment. It was reduced across different isolates.
691868-88-9	RO8191 RO8191 is an agonist of interferon α receptor type 2 (IFNAR2) effective against HCV with EC50 value of 200 nM. RO8191 phosphorylates STAT1 and STAT2, which functions as a gateway to the type I IFN signal cascade, and stimulates the phosphorylation of STAT3, 5 and 6.
78763-58-3	Deapio platycodin D Deapioplatycodin D is a triterpenoid saponin isolated from Platycodon grandiflorum, with anti-HCV activity.
801283-95-4	Faldaprevir Faldaprevir, also called as BI 201335, is a potent, once-daily (QD), hepatitis C virus (HCV) NS3/4A protease inhibitor with the potential to treat HCV infection. Faldaprevir (BI 201335) is undergoing testing in a Phase II clinical study in Hepatitis C released by Trek Therapeutics.
802835-01-4	NCI-B16
817204-33-4	PSI-6130 PSI-6130 is a potent and selective inhibitor of HCV NS5B polymerase. It is metabolized to two pharmacologically active species in primary human hepatocytes.
850876-88-9	Danoprevir Danoprevir(ITMN-191;R7227; RO5190591;RG7227) is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A.
851305-26-5	LJ001
863884-77-9	Deleobuvir Deleobuvir (BI 207127) is a potent non-nucleoside hepatitis C virus (HCV) NS5B polymerase inhibitor.
865466-24-6	Narlaprevir Narlaprevir is a potent, selective, orally bioavailable inhibitor of the hepatitis C virus (HCV) nonstructural protein 3 serine protease that is primarily metabolized by the cytochrome P450-3A4 system.
869218-90-6	AL-9
869901-69-9	MK-2048 MK-2048 is a second generation integrase inhibitor (IC50=2.6 nM). It can inhibits the HIV enzyme integrase 4 times longer than raltegravir.
870142-71-5	ACH-806 ACH-806 is a Hepatitis C virus NS3 protein inhibitor. It can inhibit viral RNA replication in HCV replicon cells and is active in genotype 1 HCV-infected patients in a proof-of-concept clinical trial. But Phase-II for Hepatitis C treatment was discontinued.
872201-68-8	Antiviral agent 44

※ Please kindly note that our services are for research use only.